KID syndrome is a congenital ectodermal dysplasia characterized by the association of keratitis, hyperkeratotic skin lesions and neurosensorial hearing loss. Ocular involvement occurs in 95% of patients. Although KID syndrome cutaneous manifestations have been studied in-depth, the treatment and prognosis of ophthalmic impairment have not been described in detail. At present, the treatment of t...

CLINICAL CASE An 81-year-old man presented with stage 2 retinal angiomatous proliferation (RAP) as identified by fluorescein angiography and optical coherence tomography (OCT), and was shown to have a visual acuity (VA) of 20/40. One week after an intravitreal injection of bevacizumab (1.25 mg) the VA improved to 20/25, and the OCT showed a reduction of both intraretinal edema and pigment epith...

Editor, A nti-VEGF agents, primarily bevacizumab, are emerging as a successful therapy for retinopathy of prematurity (ROP), particularly in aggressive posterior disease (Spandau et al. 2013). Concerns exist however regarding dosage, timing, duration of follow-up and long-term visual function. We conducted a prospective case– control study in 14 infants with symmetrical zone 1 or posterior zone...

Recognition of the role of vascular endothelial growth factor (VEGF) in developing the rich vascularity of glioblastomas, which contributes to their growth and resistance to radiation, surgery, and chemotherapy, has led to clinical trials of agents targeting VEGF or VEGF receptors 1 and 2. VEGF has been targeted with the mouse anti-human VEGF antibody avastin (bevacizumab), which has undergone ...